Clinical Trials

Study Title:
A Phase 3, Randomized, Double blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III IV Melanoma (RELATIVITY 098)

For more information about the trial above please contact the study team:

Principal Investigator, Daniel Reuben, at reubend@musc.edu.

Study Coordinator, Jennifer Kinsey, at kinsejen@musc.edu.